Further, antibodies targeting immune checkpoints such as TIGIT, PD-1, and TIM-3 have theoretical potential, as blocking these checkpoints with specific antibodies helps in reversing the diminished NK cytolytic activity in AML patients. This evidence concerns the gene TIGIT and acute myeloid leukemia.